Google
SPRY — ARS PHARMACEUTICALS, INC (Healthcare >> Biotechnology)
SPRY FAQ
What is SPRY's ROE?
ARS PHARMACEUTICALS, INC reports a Return on Equity (ROE) of -322.92%.
What is SPRY's dividend yield?
ARS PHARMACEUTICALS, INC offers a dividend yield of 0.00%.
What is SPRY's Deepscope Quality Score?
Deepscope rates SPRY's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy SPRY?
Deepscope's AI Timing Score for SPRY is 63 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does SPRY belong to?
ARS PHARMACEUTICALS, INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 8.56
Price
-0.51
(-5.62%)
Day Change
|
|
|---|
SPRY, the overall quality is not good ( Quality = 15) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 87 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 8.56 |
| PBV / Sector |
13.77 / 4.63
|
| Earning Per Share | -2.01 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
14.66 M
GREAT
|
| Average 1W Daily Value |
12.22 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
56% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:09:21 |
| Symbol | SPRY |
| Name | ARS PHARMACEUTICALS, INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 99.30 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 844.08 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 11682 El Camino Real, San Diego, CA, United States, 92130
Phone: 858 771 9307
Website: https://ars-pharma.com
Employees: 154
Sector: Healthcare >> Biotechnology
Description: ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
